As of Wednesday close, Verona Pharma plc’s (NASDAQ:VRNA) stock was up $0.1, moving up 0.80 percent to $12.56. The average number of shares traded per day over the past five days has been 137,780 shares. 5 times new highs have been achieved over the past 5 days, with a $0.51 gain in that time frame. In the last twenty days, the average volume was 222,850, while in the previous 50 days, it was 206,212.
Since last month, VRNA stock rose 11.64%. Shares of the company fell to $9.76 on 10/24/22, the lowest level in the past month. A 52-week high of $14.69 was reached on 08/09/22 after having rallying from a 52-week low of $3.41. Since the beginning of this year, VRNA’s stock price has risen by 86.90% or $5.84, and marked a new high 5 times. However, the stock has declined by -14.50% since its 52-week high.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
VRNA stock investors should be aware that Verona Pharma plc (VRNA) stock had its last reported insider trading activity 23 days ago on Nov 01. Hahn Mark W, the Chief Financial Officer of the company, disposed of 13,160 shares for $1.67 on Nov 01. It resulted in a $22,011 divestment by the insider. Rickard Kathleen A. sold 28,752 shares at an average price of $1.64 on Nov 01. The insider now owns 3,091,024 shares following the transaction. On Nov 01, President and CEO ZACCARDELLI DAVID sold 32,904 shares at $1.67 apiece. The transaction was valued at $55,035.
In the three months ended June 29, Verona Pharma plc’s quick ratio stood at 8.00, while its current ratio was 8.00, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.02, and the total debt-to-equity ratio was 0.02. Based on annual data, VRNA earned $113.31 million in gross profit and brought in $40.0 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -47.90%. Return on equity (ROE) for the past 12 months was -52.40%.
In Verona Pharma plc’s quarter-end financial report for June 29, it reported total debt of $5.04 million. While analysts expected Verona Pharma plc to report -$0.38 quarterly earnings, the actual figure was -$0.32 per share, beating the consensus estimate by 15.80%. During the quarter, the company generated -$14.95 million in EBITDA. The liabilities of Verona Pharma plc were 37.39 million at the end of its most recent quarter ended June 29, and its total debt was $5.58 million. The value of shareholders’ equity is $75.62 million.
This quick technical analysis looks at Verona Pharma plc’s (VRNA) price momentum. With a historical volatility rate of 25.30%, the RSI 9-day stood at 58.34% on 23 November.
With respect to its five-day moving average, the current Verona Pharma plc price is up by +4.23% percent or $0.51. At present, VRNA shares trade +8.28% above its 20-day simple moving average and +192.09% percent above its 100-day simple moving average. However, the stock is currently trading approximately +16.84% above its SMA50 and +115.44% above its SMA200.
Stochastic coefficient K was 50.37% and Stochastic coefficient D was 43.82%, while ATR was 0.70. Given the Stochastic reading of 53.48% for the 14-day period, the RSI (14) reading has been calculated as 58.64%. As of today, the MACD Oscillator reading stands at 0.16, while the 14-day reading stands at 0.13.
Verona Pharma plc (VRNA) has been rated Buy by analysts. According to 0 brokerage firms, VRNA is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Verona Pharma plc stock as buy, with 7 recommending it as overweight.
With a median target price of $27.00, the current consensus forecast for the stock is $17.00 – $31.00. Based on these forecasts, analysts predict Verona Pharma plc (VRNA) will achieve an average price target of $25.43.